FOLD - Amicus Therapeutics reports preliminary 2020 revenue and 2021 outlook

Amicus Therapeutics (FOLD) provides preliminary Galafold revenue for FY 2020 to ~$261M exceeding guidance of $250-$260M, driven by strong adoption and patient adherence.To achieve continued double-digit growth and Galafold revenue of at least $300M for FY 2021.The Co. strengthened Galafold IP portfolio which now includes 24 issued patents including 13 patents through 2038.The Pompe Phase 3 PROPEL study last patient, last visit complete with data expected in 1Q2021.Also, AT-GAA Pompe clinical and CMC milestones are on-track to support 2021 BLA and MAA.Multiple data and manufacturing updates and advancements planned across industry-leading rare disease gene therapy portfolio.The current cash position is sufficient to achieve self-sustainability without the need for future dilutive financing.

For further details see:

Amicus Therapeutics reports preliminary 2020 revenue and 2021 outlook